

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
2 December 2004 (02.12.2004)

PCT

(10) International Publication Number  
**WO 2004/103955 A1**

(51) International Patent Classification<sup>7</sup>: C07C 317/46,  
A61K 31/216, A61P 29/00

(74) Agent: OGILVY, RENAULT; 1981 McGill College Av-  
enue, Suite 1600, Montreal, Québec H3A 2Y3 (CA).

(21) International Application Number:  
PCT/CA2004/000314

(22) International Filing Date: 1 March 2004 (01.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/452,124 5 March 2003 (05.03.2003) US

(71) Applicant (for all designated States except US):  
MERCK FROSST CANADA & CO. [CA/CA]; 16711  
Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERTHELETTE,  
Carl [CA/CA]; 16711 Trans-Canada Highway, Kirkland,  
Quebec H9H 3L1 (CA). LI, Lianhai [CN/CA]; 16711  
Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).  
STURINO, Claudio [CA/CA]; 16711 Trans-Canada  
Highway, Kirkland, Quebec H9H 3L1 (CA). WANG,  
Zhaoyin [CA/CA]; 16711 Trans-Canada Highway, Kirk-  
land, Quebec H9H 3L1 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS



(I)

(57) Abstract: The invention encompasses novel compounds of Formula (I), which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I). The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

## TITLE OF THE INVENTION

NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS  
CYCLOOXYGENASE-2 INHIBITORS

## 5 BACKGROUND OF THE INVENTION

Selective inhibitors of cyclooxygenase-2 are a sub-class of the class of drugs known as non-steroidal antiinflammatory drugs (NSAIDs). The NSAIDs are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process but are also active in affecting other prostaglandin-regulated processes not associated with the  
10 inflammation process. Thus, use of high doses of most common NSAIDs can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to NSAIDs is the use of corticosteroids, which have even more drastic side effects, especially when long term therapy is involved.

Previous NSAIDs have been found to prevent the production of prostaglandin by  
15 ~~inhibiting enzymes in the human arachidonic acid/prostaglandin pathway including the enzyme~~  
cyclooxygenase (COX). The discovery that there are two isoforms of the COX enzyme, the first, COX-1, being involved with physiological functions and the second, COX-2, being induced in inflamed tissue, has given rise to a new approach. While conventional NSAIDs block both forms of the enzyme, the identification of the inducible COX-2 enzyme associated with  
20 inflammation has provided a viable target of inhibition which more effectively reduces inflammation and produces fewer and less drastic side effects. Many compounds which have activity as COX-2 inhibitors have been identified, including rofecoxib (VIOXX®), etoricoxib (ARCOXIA™), celecoxib (CELEBREX®) and valdecoxib (BEXTRA™), and much research continues in this area.

25 Many patients suffering from a chronic cyclooxygenase-2 mediated disease or condition are elderly and thus are at increased risk for thrombotic cardiovascular events, such as stroke, myocardial ischemia, myocardial infarction, angina pectoris, transient ischemic attack (TIA; amaurosis fugax), reversible ischemic neurologic deficits, and any similar thrombotic event in any vascular bed (splanchnic, renal, aortic, peripheral, etc.). Moreover, there is evidence  
30 that patients with chronic inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus are at increased risk for thrombotic cardiovascular events. It is desirable that such patients receive appropriate therapy to reduce their risk of such events, such as low-dose aspirin therapy. However, it has been reported that the co-administration of aspirin and a selective COX-2 inhibitor in a rat model resulted in substantially more severe gastric injury than


is produced with either agent alone. See Fiorucci et al., *Gastroenterology*, vol. 123, pp. 1598-1606, 2002. Thus, the major advantage that COX-2 selective inhibitors have over NSAIDS may be substantially or completely offset by the concomitant use of aspirin.

NO-releasing forms of non-steroidal anti-inflammatory drugs are known in the art and are reported to have improved gastrointestinal and cardiovascular safety profiles over their conventional NSAID counterparts. Furthermore, NO-releasing forms of selective cyclooxygenase-2 selective inhibitors are disclosed in WO 01/45703, published on June 28, 2001.

The present invention provides for novel nitrosated prodrugs for cyclooxygenase-2 selective inhibitors that are useful for treating cyclooxygenase-2 mediated diseases or conditions and can be administered alone or in combination with low-dose aspirin. The invention provides efficacy in treating chronic cyclooxygenase-2 mediated diseases or conditions, effectively reduces the risk of thrombotic cardiovascular events and potentially renal side effects and at the same time reduces the risk of GI ulceration or bleeding.

#### SUMMARY OF THE INVENTION


The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases:



The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

## DETAILED DESCRIPTION OF THE INVENTION

The invention encompasses the novel compounds of Formula I as prodrugs which convert *in vivo* to diaryl-2-(5H)-furanones and are useful in the treatment of cyclooxygenase-2 mediated diseases:



or a pharmaceutically acceptable salt thereof, wherein:

10  $n$  is an integer from 3 to 6;

$R^1$  is selected from the group consisting of:

- 15 (a)  $S(O)_2CH_3$ ,  
 (b)  $S(O)_2NH_2$ ,  
 (c)  $S(O)_2NHC(O)CF_3$ ,  
 (d)  $S(O)(NH)CH_3$ ,  
 (e)  $S(O)(NH)NH_2$ ,  
 (f)  $S(O)(NH)NHC(O)CF_3$ ,  
 (g)  $P(O)(CH_3)OH$ , and  
 20 (h)  $P(O)(CH_3)NH_2$ ;

$R^2$  and  $R^3$  each are independently selected from the group consisting of:

- 25 (a) hydrogen,  
 (b) halo,  
 (c)  $C_{1-6}$ alkoxy,  
 (d)  $C_{1-6}$ alkylthio,  
 (e) CN,  
 (f)  $CF_3$ ,  
 (g)  $C_{1-6}$ alkyl, and  
 (h)  $N_3$ ;

R<sup>4</sup> is selected from the group consisting of

- (a) -C(O)-C<sub>1-4</sub>alkyl and
- (b) -C(O)-(CH<sub>2</sub>)<sub>m</sub>-N(R<sup>5</sup>)(R<sup>6</sup>);

5 m is an integer from 1 to 4; and

R<sup>5</sup> and R<sup>6</sup> are each independently selected from the group consisting of hydrogen and C<sub>1-4</sub> alkyl, optionally substituted with 1 to 3 halo groups.

The variable n is an integer from 3 to 6. Thus, the linking the group can be  
10 pentyl, hexyl, heptyl and octyl.

An embodiment of the invention encompasses a compound of Formula I wherein R<sup>1</sup> is S(O)<sub>2</sub>CH<sub>3</sub>, and R<sup>2</sup> and R<sup>3</sup> are both hydrogen.


Another embodiment of the invention encompasses a compound of Formula I wherein n is 3, 4 or 5.

15 Another embodiment of the invention encompasses a compound of Formula I wherein n is 4.


Another embodiment of the invention encompasses a compound of Formula I wherein R<sup>4</sup> is acetyl.

20 Another embodiment of the invention encompasses a compound of Formula I wherein R<sup>4</sup> is glycyl.

Another embodiment of the invention encompasses a compound which is



Another embodiment of the invention encompasses a compound which is



or a pharmaceutically acceptable salt thereof.

The invention also encompasses a pharmaceutical composition comprising a  
 5 compound of Formula I and a pharmaceutically acceptable carrier.

The invention also encompasses a method of treating an inflammatory disease  
 susceptible to treatment with a non-steroidal anti-inflammatory agent comprising administering  
 to a patient in need of such treatment a non-toxic therapeutically effective amount of a  
 compound of Formula I. Within this embodiment is encompassed the above method wherein the  
 10 patient is also at risk of a thrombotic cardiovascular event and on aspirin therapy to reduce the  
 risk of the thrombotic cardiovascular event.

Another embodiment of the invention encompasses a method of treating  
 cyclooxygenase mediated diseases advantageously treated by an active agent that selectively  
 inhibits COX-2 in preference to COX-1 comprising administering to a patient in need of such  
 15 treatment a non-toxic therapeutically effective amount of a compound of Formula I. Within this  
 embodiment is encompassed the above method wherein the patient is also at risk of a thrombotic  
 cardiovascular event and on aspirin therapy to reduce the risk of the thrombotic cardiovascular  
 event.

Another embodiment of the invention encompasses a method for treating a  
 20 chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic  
 cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic  
 cardiovascular event comprising orally concomitantly or sequentially administering to said  
 patient a compound of Formula I in an amount effective to treat the cyclooxygenase-2 mediated  
 disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic  
 25 cardiovascular event. Within this embodiment is encompassed the above method wherein the  
 compound of Formula I is administered orally on a once daily basis. Within this embodiment is  
 encompassed the above method wherein the compound of Formula I is administered orally on a  
 twice daily basis. Within this embodiment is encompassed the above method wherein the  
 chronic cyclooxygenase-2 selective mediated disease or condition is selected from the group

consisting of: osteoarthritis, rheumatoid arthritis and chronic pain. Within this embodiment is encompassed the above method wherein aspirin is administered at a dose of about 30 mg to about 1 g. Within this embodiment is encompassed the above method wherein aspirin is administered at a dose of about 80 to about 650 mg. Within this embodiment is encompassed the above method wherein aspirin is administered at a dose of about 81 mg or about 325 mg. Within this embodiment is encompassed the above method wherein aspirin is orally administered once daily.

The invention also encompasses a pharmaceutical composition comprising a compound of Formula I and aspirin in combination with a pharmaceutically acceptable carrier.

Another embodiment of the invention encompasses a compound according to Claim 1 wherein:  $R^1$  is selected from the group consisting of:  $S(O)_2CH_3$  and  $S(O)_2NH_2$ ;  $R^2$  and  $R^3$  each are independently selected from the group consisting of: hydrogen and halo; and  $R^4$  is  $-C(O)-C_{1-4}alkyl$ . Within this embodiment of the invention is encompassed a compound of Formula I wherein  $n$  is 4 or 5.

The term "halogen" or "halo" includes F, Cl, Br, and I.

The term "alkyl" means linear or branched structures and combinations thereof, having the indicated number of carbon atoms. Thus, for example,  $C_{1-6}alkyl$  includes methyl, ethyl, propyl, 2-propyl, *s*- and *t*-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "alkoxy" means alkoxy groups of a straight or branched configuration having the indicated number of carbon atoms.  $C_{1-6}alkoxy$ , for example, includes methoxy, ethoxy, propoxy, isopropoxy, and the like.

The term "alkylthio" means alkylthio groups having the indicated number of carbon atoms of a straight or branched configuration.  $C_{1-6}alkylthio$ , for example, includes methylthio, propylthio, isopropylthio, and the like.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both *E* and *Z* geometric isomers.

The term "treating a chronic cyclooxygenase-2 mediated disease or condition" means treating or preventing any chronic disease or condition that is advantageously treated or prevented by inhibiting the cyclooxygenase-2 enzyme. The term includes the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, migraine (acute and prophylactic treatment), toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases

(osteoarthritis), gout and ankylosing spondylitis, acute, subacute and chronic musculoskeletal pain syndromes such as bursitis, burns, injuries, and pain following surgical and dental procedures as well as the preemptive treatment of surgical pain. In addition, the term includes the inhibition cellular neoplastic transformations and metastatic tumor growth and hence the treatment of cancer. The term also includes the treatment of endometriosis and Parkinson's disease as well as the treatment of cyclooxygenase-mediated proliferative disorders such as may occur in diabetic retinopathy and tumor angiogenesis. The term "treating" encompasses not only treating a patient to relieve the patient of the signs and symptoms of the disease or condition but also prophylactically treating an asymptomatic patient to prevent the onset or progression of the disease or condition.

A "thrombotic cardiovascular event" is defined as any sudden event of a type known to be caused by platelet aggregation, thrombosis, and subsequent ischemic clinical events, including thrombotic or thromboembolic stroke, myocardial ischemia, myocardial infarction, angina pectoris, transient ischemic attack (TIA; amaurosis fugax), reversible ischemic neurologic deficits, and any similar thrombotic event in any vascular bed (splanchnic, renal, aortic, peripheral, etc.).

The term "patient in need of such treatment and at risk of a thrombotic cardiovascular event" means a patient in need of both treatment for a cyclooxygenase-2 mediated disease and also at risk of a thrombotic cardiovascular event. One skilled in the art can diagnose a patient that is in need of treatment for a cyclooxygenase-2 mediated disease or condition and also at risk of suffering a thrombotic cardiovascular event. For example, such a patient may be over the age of 50 with osteoarthritis and with a previous myocardial infarction. Other risk factors for a thrombotic cardiovascular event include hypertension, hypercholesterolemia, diabetes mellitus, chronic renal impairment, smoking, and any prior personal or family history of such an event. Administration of the drug combination to the patient includes both self-administration and administration to the patient by another person.

The term "amounts that are effective to treat" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician. The term also encompasses the amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. The inhibitor of cyclooxygenase-2 may be administered at a dosage level up to conventional dosage levels for NSAIDs. Suitable dosage levels of the compound of Formula I



used in the present invention are described below. The compound may be administered on a regimen of once or twice per day.

The term "amount effective to reduce the risk of" means the amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. Aspirin is administered at a dose of about 30 mg to about 1 g once daily, preferably at a dose of about 80 mg to about 650 mg.

The term "concomitantly administering" means administering the agents substantially concurrently. The term "concomitantly administering" encompasses not only administering the two agents in a single pharmaceutical dosage form but also the administration of each active agent in its own separate pharmaceutical dosage formulation. Where separate dosage formulations are used, the agents can be administered at essentially the same time, i.e., concurrently.

The term "sequentially administering" means administering the agents at separately staggered times. Thus, agents can be sequentially administered such that the beneficial pharmaceutical effect of aspirin and a compound of the present invention are realized by the patient at substantially the same time. Thus, for example, if a compound of the present invention and aspirin are both administered on a once a day basis, the interval of separation between sequential administration of the two agents can be up to twelve hours apart.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" include salts prepared from bases that result in non-toxic pharmaceutically acceptable salts, including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine,

piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from acids that result in pharmaceutically acceptable salts, including inorganic and organic acids.

- 5 Such acids include acetic, adipic, aspartic, 1,5-naphthalenedisulfonic, benzenesulfonic, benzoic, camphorsulfonic, citric, 1,2-ethanedisulfonic, ethanesulfonic, ethylenediaminetetraacetic, fumaric, glucoheptonic, gluconic, glutamic, hydriodic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, 2-naphthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, pivalic, propionic, salicylic, stearic, succinic, sulfuric, tartaric, 10 p-toluenesulfonic acid, undecanoic, 10-undecenoic, and the like.

- The compounds of Formula I are prodrugs of cyclooxygenase-2 selective inhibitors which covert *in vivo* to diaryl-2-(5H)-furanones. The compounds also liberate nitric oxide *in vivo*, which is believed to contribute to an improved gastrointestinal and potentially renal safety profile. As such, the compounds of the present invention may be co-dosed with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions, effectively 15 reduce the risk of thrombotic cardiovascular events and potentially renal side effects and at the same time reduce the risk of GI ulceration or bleeding. Thus, patients with hypertension and cardiovascular disease, as well as potentially patients with renal insufficiency, would actively benefit from being administered compounds of the present invention over NSAIDs and 20 cyclooxygenase-2 selective inhibitors currently available.

- By virtue of the cyclooxygenase-2 activity of the active moiety of the prodrugs of the present invention, the compounds of Formula I are therefore useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, 25 dysmenorrhea, headache, migraine (acute and prophylactic treatment), toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, acute, subacute and chronic musculoskeletal pain syndromes such as bursitis, burns, injuries, and pain following surgical and dental procedures as well as the preemptive treatment of surgical pain. In addition, such a 30 compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. Compounds of Formula I may also be useful for the treatment or prevention of endometriosis and Parkinson's disease.

Compounds of Formula I will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.

By virtue of the high cyclooxygenase-2 (COX-2) activity and/or the selectivity for  
5 cyclooxygenase-2 over cyclooxygenase-1 (COX-1) of the active moiety of the prodrugs of the invention as defined above, compounds of Formula I will prove useful as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of  
10 gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g. impaired renal function); those prior to surgery or taking anticoagulants; and those susceptible to NSAID induced asthma.

Similarly, compounds of Formula I will be useful as a partial or complete  
15 substitute for conventional NSAIDs in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including  
20 acetaminophen or phenacetin; opioid analgesics, such as codeine, fentanyl, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, buprenorphine, butorphanol, dezocine, nalbuphine and pentazocine; a potentiator including caffeine; an H<sub>2</sub>-antagonist; aluminum or magnesium hydroxide; simethicone; a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine,  
25 naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; a sedating or non-sedating antihistamine; and a proton pump inhibitor, such as omeprazole. For the treatment or prevention of migraine, the invention also encompasses co-administration with a 5-HT agonist such as rizatriptan, sumatriptan, zolmitriptan and naratriptan. In addition the  
30 invention encompasses a method of treating cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.

Compounds of the present invention are prodrugs of inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of cyclooxygenase-2 mediated diseases as enumerated above. This activity is illustrated by their ability to selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Accordingly, the ability of the compounds of this invention to convert to the active compound and thus treat cyclooxygenase mediated diseases can be demonstrated by measuring the amount of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) synthesized in the presence of arachidonic acid, cyclooxygenase-1 or cyclooxygenase-2 and a compound of Formula I as illustrated in the assays that follow. The IC<sub>50</sub> values represent the concentration of inhibitor required to return PGE<sub>2</sub> synthesis to 50% of that obtained as compared to the uninhibited control. For the treatment of any of these cyclooxygenase mediated diseases, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. Compounds of the invention may be administered via the buccal or sublingual mucosa in the oral cavity. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Compounds of the invention may also be administered through the nasal, pulmonary (inhalation aerosol) or ocular route. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.

As indicated above, pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be

coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxypropylmethy-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxyctanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Liquid formulations include the use of self-emulsifying drug delivery systems and NanoCrystal® technology. Cyclodextrin inclusion complexes can also be utilized.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting

agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and  
10 flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be  
15 formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride  
20 solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Compounds of Formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug  
25 with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical  
30 application shall include mouth washes and gargles.)

Pharmaceutical compositions of the invention may also utilize absorption enhancers such as tween 80, tween 20, Vitamin E TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) and Gelucire®.

Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day, preferably 2.5 mg to 1 g per patient per day.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg. Dosage amounts of 4 mg, 8 mg, 18 mg, 20 mg, 36 mg, 40 mg, 80 mg, 160 mg, 320 mg and 640 mg may also be employed. The following table exemplifies formulations that may be employed for the present invention.

Table 1

## Wet Granulated Tablet Composition

Ingredient	Amount Per Tablet		
	Example 1		
Example 1	4.0 mg	20.0 mg	80.0 mg
Lactose Monohydrate	29.1 mg	28.1 mg	112.4 mg
Microcrystalline Cellulose	60.0 mg	45.0 mg	180.0 mg
Hydroxypropyl Cellulose	3.0 mg	3.0 mg	12.0 mg
Croscarmellose Sodium	3.0 mg	3.0 mg	12.0 mg
Red Ferric Oxide	0.4 mg	0.4 mg	1.6 mg
Magnesium Stearate	0.5 mg	0.5 mg	2.0 mg

Tablet dose strengths of between 4 mg and 625 mg of the active ingredient can be accommodated by varying the total tablet weight and the ratio of the first three ingredients. The red ferric oxide indicated in Table 1 can be substituted with any pharmaceutically acceptable color or by a film-coat.

It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex,

diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

### Methods of Synthesis

Stilbene derivatives useful as cyclooxygenase-2 selective inhibitors are disclosed in U.S. No. 5,849,943, which is hereby incorporated by reference in its entirety.


Diaryl-2-(5H)-furanones useful as COX-2 inhibitors are known in the art and disclosed in U.S. No. 5,474,995, which is hereby incorporated by reference in its entirety.

Methods for making diaryl-2-(5H)-furanones useful as COX-2 inhibitors are disclosed in U.S.

No. 5,840,924, which is hereby incorporated by reference in its entirety. Rofecoxib, sold under the tradename VIOXX, is known in the art and commercially available.

Compounds of the invention can be synthesized according to the following synthetic schemes:

### **Scheme 1**



### Abbreviations used in Scheme 1


D.M. = Dess-Martin reagent

DMF = N,N-dimethylformamide

HF.pyr = hydrogen fluoride pyridine (70/30)



Scheme 2

5 Abbreviations used in Scheme 2

D.M. = Dess-Martin reagent

DMAP = 4-(dimethylamino)pyridine

DMF = N,N-dimethylformamide

EDCI = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

10 HCl = hydrochloric acid

HF.pyr = hydrogen fluoride pyridine (70/30)

t-Boc-glycine = N-*tert*-butoxycarbonyl-glycine

TFA = trifluoroacetic acid

### Assays for Determining Biological Activity

The compounds of Formula I can be tested using the following assays to determine their biological activity.

#### 5 Inhibition of Cyclooxygenase Activity

Compounds are tested as inhibitors of cyclooxygenase activity in whole cell and microsomal cyclooxygenase assays. Both of these assays measure prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) synthesis in response to arachidonic acid, using a radioimmunoassay. Cells used for whole cell assays, and from which microsomes are prepared for microsomal assays, are human  
10 osteosarcoma 143 cells (which specifically express cyclooxygenase-2) and human U-937 cells (which specifically express cyclooxygenase-1). In these assays, 100% activity is defined as the difference between prostaglandin E<sub>2</sub> synthesis in the absence and presence of arachidonate addition. IC<sub>50</sub> values represent the concentration of putative inhibitor required to return PGE<sub>2</sub> synthesis to 50% of that obtained as compared to the uninhibited control.

#### 15 A. Microsomal Cyclooxygenase Assay

Cox microsomal fractions are prepared as previously described (Percival et al., Arch. Biochem. Biophys. (1994) 315:111-118). The enzyme reactions are performed in 50 mM KPi pH 8.0, 1  $\mu$ M heme, 1 mM phenol supplemented with 10  $\mu$ g/ml of each Cox-1 or Cox-2  
20 microsomal fractions. 1  $\mu$ l DMSO or test compound (100 fold stock concentrated in DMSO) are added to 100  $\mu$ l buffer. The enzyme reaction is initiated 15 minutes later by the addition of 10  $\mu$ l of 100  $\mu$ M arachidonic acid. The enzyme reaction is allowed to proceed for 5 minutes at room temperature before being stopped by the addition of 10  $\mu$ l 1 N HCl. PGE<sub>2</sub> levels are then determined by EIA (Assay Designs) using the manufacturer's instruction.

This assay may be used to demonstrate that the unconverted prodrugs of the  
25 instant invention are inactive against both COX-1 and COX-2.

#### B. Human Whole Blood Cyclooxygenase Assay

##### Rationale

Whole blood provides a protein and cell-rich milieu for the study of biochemical  
30 efficacy of anti-inflammatory compounds such as COX-2 inhibitors and NSAIDs. To study the inhibitory activities of these compounds on the two isoforms of cyclooxygenase (COX-1 and COX-2), human blood is either stimulated with lipopolysaccharide (LPS) for 24 hours to induce COX-2 or the blood is allowed to clot spontaneously to activate COX-1. The production of

prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and thromboxane B<sub>2</sub> (TXB<sub>2</sub>) are measured by immunoassay at the end of the incubation as readouts of COX-2 and COX-1 activity, respectively.

### Methods

5 Human whole blood assays for COX-1 and COX-2 activity, previously reported (Brideau et al, 1996) are performed as described below.

#### 1. COX-2 (LPS-induced PGE<sub>2</sub> production):

10 Fresh blood is collected in heparinized tubes by venipuncture from healthy male volunteers. These subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. The blood is initially pre-incubated with bacterial lipopolysaccharide (LPS) at 100 µg/ml (Sigma Chem, #L-2630 from *E. coli*, serotype 0111:B4; diluted in 0.1% w/v bovine serine albumin in phosphate buffered saline). Five minutes later, 500 µL aliquots of the LPS-treated blood are incubated with 2 µL vehicle (DMSO) or 2  
15 µL of test compounds in DMSO for 24 hr at 37°C (for induction of COX-2). Unstimulated control blood at time zero (no LPS) is used as blank. At the end of the 24 hr incubation, the blood is centrifuged at 3,000 rpms for 10 min at 40°C to obtain plasma. The plasma is assayed for PGE<sub>2</sub> using an enzyme immunoassay kit (Assay Designs, 901-001) according to the manufacturer's instructions.

20

#### 2. COX-1 (clotting-induced TXB<sub>2</sub> production):

25 Fresh blood from male or female volunteers is collected into vacutainers containing no anticoagulants. These subjects have no apparent inflammatory conditions and have not taken any NSAIDs for at least 7 days prior to blood collection. Aliquots of 500 µL are immediately transferred to polypropylene tubes preloaded with 2 µL of DMSO or 2 µL of test compounds. The tubes are vortexed and incubated at 37°C for 1 h to allow the blood to clot. At the end of the incubation, serum is obtained by centrifugation (3,000 rpm for 10 min at 40°C). The serum is obtained and is assayed for TXB<sub>2</sub> using an enzyme immunoassay kit (Assay Designs, 901-002) according to the manufacturer's instructions.

30

### Results

The IC<sub>50</sub> value for the inhibition of PGE<sub>2</sub> production in a human whole blood assay by Example 1 was 0.22 ± 0.04 µM (n=6). The clotting-induced TXB<sub>2</sub> level was inhibited by Example 1 with an IC<sub>50</sub> of 7.8 ± 2.6 µM (n=3). Thus, Example 1 is prodrug of a potent and

selective inhibitor of COX-2 as compared to COX-1 (COX1/COX2: 35-fold) in an in vitro human peripheral blood assay.

#### Representative Rat Paw Edema Assay – Protocol

5

##### Rationale

The carrageenan-induced rat paw edema assay is an established assay for evaluating the efficacy of conventional, non-selective NSAIDs in acute inflammation (Winter and Flataker, 1965; Mukherjee et al., 1996; Vinegar et al., 1987).

10

##### Methods

Male Sprague-Dawley rats (200 – 250 g) are fasted for 16 - 18 h prior to oral administration of either the vehicle (0.5% methocel) or test compound. One hour later, a line was drawn using a permanent marker at a level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume ( $V_0$ ) is measured using a plethysmometer (Ugo-Basile, Italy) based on the Archimedes principle of water displacement. The rats are then injected subplantarly with 0.05 mL of a 1% carrageenan (Sigma Chem.) solution in saline using a syringe with a 27-gauge needle (i.e. 500  $\mu$ g carrageenan per paw). Three hours later, the paw volume ( $V_3$ ) is measured again and the increases in paw volume ( $V_3 - V_0$ ) is calculated. Paw edema is compared with the vehicle-control group and the percent inhibition calculated taking the values in the control group as 0 %.

20

##### Results

Example 1 (1 hr pretreatment) inhibited the carrageenan-induced edema response dose-dependently with 49% inhibition at 1 mg/kg. Example 1 is a potent anti-inflammatory compound with a potency comparable to that of its corresponding active moiety, rofecoxib, in a model of acute inflammation.

25

#### NSAID-Induced Gastropathy In Rats

30

##### Rationale

The major side effect of conventional NSAIDs is their ability to produce gastric lesions in man. Rats are sensitive to the actions of NSAIDs and have been used commonly in the past to evaluate the gastrointestinal side effects of current conventional NSAIDs. In the

present assay, NSAID-induced gastrointestinal damage is observed by measuring urinary  $^{51}\text{Cr}$  excretion after oral dosing of  $^{51}\text{Cr}$ -EDTA. Urinary  $^{51}\text{Cr}$  excretion is a well-established and sensitive technique to detect gastrointestinal integrity in animals and man.

5 Methods

Male Sprague-Dawley rats (150-200 g) are administered orally a test compound either once (acute dosing) or in multiple doses for a few days (chronic dosing). Immediately after the administration of the last dose, the rats are given an oral dose of  $^{51}\text{Cr}$ -EDTA (10  $\mu\text{Ci}/\text{rat}$ ). The animals are placed individually in metabolism cages with food and water *ad lib*.

- 10 Urine is collected for a 24 hr period and  $^{51}\text{Cr}$  urinary excretion is calculated as a percent of total ingested dose.

Protein-Losing Gastrophathy in Squirrel Monkeys

15 Rationale

Protein-losing gastrophathy (manifested as appearance of circulating cells and plasma proteins in the GI tract) is a significant and dose-limiting adverse response to NSAIDs. This can be quantitatively assessed by intravenous administration of  $^{51}\text{CrCl}_3$  solution. This isotopic ion can avidly bind to cell and serum globins and cell endoplasmic reticulum.

- 20 Measurement of radioactivity appearing in feces collected for 24 hr after administration of the isotope thus provides a sensitive and quantitative index of protein-losing gastrophathy.

Methods

- 25 Groups of male squirrel monkeys (0.8 to 1.4 kg) are treated by gavage with 1% methocel or a test compounds at multiple doses for a few days. Intravenous  $^{51}\text{Cr}$  (5  $\mu\text{Ci}/\text{kg}$  in 1 ml/kg PBS) is administered 1 hr after the last drug/vehicle dose, and feces collected for 24 hr in a metabolism cage and assessed for excreted  $^{51}\text{Cr}$  by gamma-counting.  $^{51}\text{Cr}$  fecal excretion is calculated as a percent of total injected dose.

30 Rat Aortic Smooth Muscle Rings in Male Spargue-Dawley Rats

Preparation of rat aortic smooth muscle rings Male Sprague-Dawley rats (Charles River Laboratories (Wilmington, MA) are euthanized by intraperiton injection of a high dose of sodium pentobarbitone (80-100 mg/kg). The thoracic aorta is rapidly excised and immediately placed in a Petri dish containing warm (37 °C) oxygenated (95% O<sub>2</sub> and 5% CO<sub>2</sub>) Kreb's buffer

(composition per millimolar: NaCl (119); KCl (4.69);  $\text{CaCl}_2 \cdot \text{H}_2\text{O}$  (2.52);  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  (0.57);  $\text{NaHCO}_2$ , (25);  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$  (1.01) and glucose (11.1). Under a stereoscopic dissecting microscope, the aorta is cleaned, freed from adhering fat and connective tissues. The tissue is cut into ring segments, each approximately 2-3 mm in length.

5 For experiments to measure relaxation of the tissue under various conditions, a stainless steel tissue holder and an U-shaped stainless steel wire are inserted into the lumen of the aortic ring. The tissue holder anchored the ring at the bottom of the organ bath whereas the end of the U-shaped steel wire is tied with fine silk thread so that it connected to the FT-202 transducer. The tissue holder and the steel wire along with the aortic ring are then suspended in a  
10 5-ml, double-jacketed temperature-controlled glass organ bath (Radnoti Glass Technology, Inc., Monrovia, CA) filled with fresh Krebs's buffer. A mixture of 95%  $\text{O}_2$  and 5%  $\text{CO}_2$  is bubbled through a porous sintered disc at the bottom of the bath. The rings are given an initial resting tension of 1.5 g and the preparation is allowed to equilibrate at the initial tension for about 90 minutes. During this equilibration period, the bath fluid is changed every 15 minutes and  
15 replaced with fresh prewarmed ( $37^\circ\text{C}$ ) Krebs's buffer. The isometric tension of the aortic muscle at rest and its response to different stimuli are recorded on a Power Macintosh 6100 computer via a MacLab 8/S computer interface (CB Sciences, Inc, Milford, MA) after an initial amplification through a low-noise ETH-400 bioamplifier (CB Sciences, Inc, Milford, MA). Contractile responsiveness of the tissue strips is established with  $10^{-6}\text{M}$  phenylephrine, and the  
20 strips are incubated with the drug for 20 minutes to establish a steady level of contraction.

To test the relaxation effects, test compounds can be added to the phenylephrine precontracted strips in the tissue bath at cumulative concentrations of  $0.1\ \mu\text{M}$  to  $0.1\ \text{mM}$ . Concentration of test compounds may be increased only after relaxation at the previous concentration had reached a plateau level.

25

#### Gastric Erosion Model in Rats

The gastric protective effects of the combination of the present invention co-administered with aspirin may be evaluated in the following assay.

30 Male Wistar rats (200 - 250 g) were fasted for 16 - 18 h prior to use for experiment. Aspirin, rofecoxib in combination with aspirin (dosed separately), or test compound in combination with aspirin (dosed separately) were given on the morning of the experiment at a dosing volume of 1 ml/kg in 0.5% methocel. Three hr later, the animals were euthanized by  $\text{CO}_2$  inhalation and the stomach removed, rinsed in saline and prepared for imaging processing. Microscopic pictures of the stomach were taken using a digital camera and

gastric erosions were measured using an imaging software by an observer unaware of the treatment groups. The length of gastric erosions was measured in mm and the total length of all erosions from each stomach was obtained and used as gastric damage score.

- This model is also described in S. Fiorucci, et al., *Gastroenterology*, vol. 123, pp. 1598-1606, 2002 and M. Souza, et al., *Am. J. Physiol. Gastrointest. Liver Physiol.*, vol. 285, pp. G54-G61, 2003.

Example 1 was tested in the above assay and demonstrated significant gastric protection when co-dosed with aspirin as compared to rofecoxib dosed with aspirin.

#### 10 Representative Examples

The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:

- all operations were carried out at room or ambient temperature, that is, at a temperature in the range -18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals; 4.5-30 mm. Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta ( $\delta$ ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz, 400 MHz or 500 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

The following abbreviations have the indicated meanings:


Ac	=	acetyl
Boc-Glycine	=	N- <i>tert</i> -butoxycarbonyl-glycine
DIBAL	=	diisobutylaluminum hydride

DMAP	=	4-(dimethylamino)pyridine
DMF	=	N,N-dimethylformamide
EDCI	=	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
GMP	=	good manufacturing practices
HF.pyr	=	hydrogen fluoride pyridine (70/30)
IPAc	=	isopropyl acetate
TBS	=	<i>tert</i> -butyl(dimethyl)silyl
TBSCl	=	<i>tert</i> -butyl(dimethyl)silyl chloride
THF	=	tetrahydrofuran

Alkyl Group Abbreviations

Me	=	methyl
Et	=	ethyl
t-Bu	=	tertiary butyl


The Dess-Martin reagent, having the following structure, is known in the art.



See Dess, D.B.; Martin, J.C., *J. Org. Soc.*, 1983, 48, 4155.


## EXAMPLE 1

10. 6-(nitrooxy)hexyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate






Step 1: (2Z)-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-ene-1,4-diol



- 5 To a solution of 110 g of 4-(4-methanesulfonyl-phenyl)-3-phenyl-5H-furan-2-one in 1.5 L of dichloromethane stirred at  $-78^{\circ}\text{C}$ , 150 mL of DIBAL was added dropwise. The resulting mixture was warmed to room temperature and stirred overnight. The reaction mixture was then cooled to  $-78^{\circ}\text{C}$ , and 1.2 L of 1 M aqueous NaOH was added dropwise. After the addition, the resulting mixture was warmed to room temperature and the organic phase was separated. The
- 10 aqueous phase was extracted with dichloromethane. The organic phases were combined and dried over  $\text{Na}_2\text{SO}_4$ . 110 g of the titled compound was obtained after evaporation.  $^1\text{H}$  NMR (acetone- $d_6$ , 500 MHz):  $\delta$  7.69 (d, 2 H), 7.36 (d, 2 H), 7.16-7.05 (m, 5 H), 4.66 (d, 2 H), 4.63 (d, 2 H), 4.19 (t, 1 H, OH), 4.17 (t, 1 H, OH), 3.04 (s, 3 H).


- 15 Step 2: (2Z)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-en-1-ol



- To a solution of 110 g of (2Z)-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-ene-1,4-diol and 50 g of imidazole in 1 L of THF stirred at  $-78^{\circ}\text{C}$ , a solution 51 g of TBSCl in 250 mL of
- 20 dichloromethane was added dropwise. The resulting mixture was stirred at  $-78^{\circ}\text{C}$  0.5 hr. Brine was then added and then warmed to room temperature. The organic phase was separated and the


aqueous phase was extracted with EtOAc. The organic phases were combined and dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. The resulting crude material was purified by flash chromatography to afford 25.6 g of the title compound as a white solid. <sup>1</sup>H NMR (acetone-*d*<sub>6</sub>, 500 M Hz): δ 7.69 (d, 2 H), 7.37 (d, 2 H), 7.18-7.04 (m, 5 H), 4.77 (s, 2 H), 4.65 (d, 2 H), 3.96 (t, 1 H, OH), 3.03 (s, 3 H), 0.84 (s, 9 H), 0.01 (s, 6 H).

Step 3: (2*Z*)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate



To a solution of 46 g of (2*Z*)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-en-1-ol with 120 mmol of DMAP in 1 L of dichloromethane, 120 mmol of acetic anhydride was added dropwise. The resulting mixture was stirred at rt for 1 hr. The reaction mixture was loaded on a silica gel column and eluted with EtOAc to afford 50.5 g of the titled compound as a white solid. <sup>1</sup>H NMR (acetone-*d*<sub>6</sub>, 500 M Hz): δ 7.68 (d, 2 H), 7.33 (d, 2 H), 7.15-7.04 (m, 5 H), 5.16 (s, 2 H), 4.75 (s, 2 H), 3.02 (s, 3 H), 1.92 (s, 3 H), 0.81 (s, 9 H), -0.03 (s, 6 H).


Step 4: (2*Z*)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate



To a solution of 50.5 g of (2*Z*)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate in 125 mL of MeCN, 10 mL of PyHF was added and the resulted


mixture was stirred at rt for 1.5 hr. The reaction mixture was diluted with 600 mL of toluene and then loaded on silica gel column and eluted with EtOAc. The solvent was evaporated to afford 38.3 g of the titled compound.  $^1\text{H}$  NMR (acetone- $d_6$ , 500 M Hz):  $\delta$  7.68 (d, 2 H), 7.32 (d, 2 H), 7.15-7.00 (m, 5 H), 5.20 (s, 2 H), 4.62 (d, 2 H), 4.09 (t, 1 H, OH), 3.02 (s, 3 H), 1.92 (s, 3 H).

5 Step 5: (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoic acid



To a solution of 38.3 g of (2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate in 500 mL of dichloromethane, 47 g of Dess-Martin reagent was added and the resulted mixture was stirred at rt for 2 hr. Then 2 mL of water was added and the resulted mixture was stirred at rt for 1 hr. Then the mixture was filtered and evaporated. The crude thus obtained was dissolved in a solvent mixture of 200 mL of THF with 200 mL of t-BuOH. To the resulting mixture, 30 mL of 2-methyl-2-butene was added and followed by the addition of 200 mL of 1.2 M of phosphoric acid and 200 mL of 1 M of NaClO<sub>2</sub>. The resulting mixture was stirred at rt for 30 min. The organic phase was separated and the aqueous phase was extracted with EtOAc. The organic phase was combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then evaporated. The crude was purified by recrystallization from ether to afford 37 g of the titled compound as white solid.  $^1\text{H}$  NMR (acetone- $d_6$ , 500 M Hz):  $\delta$  7.76 (d, 2 H), 7.43 (d, 2 H), 7.18-7.12 (m, 3 H), 7.12-7.08 (m, 2 H), 5.24 (s, 2 H), 3.05 (s, 3 H), 1.88 (s, 3 H).


20 Step 6: 6-bromohexyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate



A solution of 2.6 g of (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoic acid and 17 g of 1,6-dibromohexane in 30 mL of DMF was stirred at rt with 1.0 g K<sub>2</sub>CO<sub>3</sub> for 1 hr.

Then saturated ammonium chloride solution was added and extracted with EtOAc. The organic layer was combined and washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the residue was purified by flash chromatography over silica gel (5-50% EtOAc/hexane) to afford 3.6 g of the titled compound as a white solid. <sup>1</sup>H NMR (acetone-*d*<sub>6</sub>, 500 MHz): δ 7.80 (d, 2 H), 7.47 (d, 2 H), 7.22-7.15 (m, 3 H), 7.12-7.05 (m, 2 H), 5.21 (s, 2 H), 4.27 (t, 2 H), 3.48 (t, 2 H), 3.08 (s, 3 H), 1.93 (s, 3 H), 1.86-1.80 (m, 2 H), 1.74-1.68 (m, 2 H), 1.50-1.41 (m, 2 H), 1.41-1.34 (m, 2 H).


Step 7: 6-(nitrooxy)hexyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate




A solution of 3.6 g of 6-bromohexyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate and 3.6 g of AgNO<sub>3</sub> in 50 mL of MeCN was heated to 85 °C for 12 min. The solvent was evaporated and the residue was stirred with EtOAc for 10 min and filtered. The solvent was evaporated and the residue was purified by flash chromatography over silica gel (5-55% EtOAc/hexane) to afford 3.24 g of the titled compound as a white solid. <sup>1</sup>H NMR (acetone-*d*<sub>6</sub>, 500 MHz): δ 7.76 (d, 2 H), 7.43 (d, 2 H), 7.18-7.13 (m, 3 H), 7.12-7.04 (m, 2 H), 5.18 (s, 2 H), 4.50 (t, 2 H), 4.24 (t, 2 H), 3.05 (s, 3 H), 1.90 (s, 3 H), 1.75-1.65 (m, 4 H), 1.44-1.31 (m, 4 H).

## EXAMPLE 2

(2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenylbut-2-enyl  
glycinate chloride




Step 1: (2Z)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl N-(*tert*-butoxycarbonyl)glycinate




To a solution of 16.4 g of (2Z)-4-[[*tert*-butyl(dimethyl)silyl]oxy]-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-en-1-ol, 1.92 g of DMAP and 7.30 g of Boc-Glycine in 125 mL of CH<sub>2</sub>Cl<sub>2</sub> at 0°C was added 8.0 g of EDCI. The reaction mixture was stirred for 4 h. Then saturated ammonium chloride solution was added and extracted with EtOAc. The organic layer was combined, washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the residue was purified by flash chromatography over silica gel (5-55% EtOAc/hexane) to afford 22 g of the titled compound as a colorless oil. <sup>1</sup>H (500 MHz, acetone-*d*<sub>6</sub>): δ 7.67 (d, 2H), 7.34 (d, 2H), 7.13-7.04 (m, 5H), 6.26 (br s, NH), 5.23 (s, 2H), 4.76 (s, 2H), 3.73 (d, 2H), 3.02 (s, 3H), 1.40 (s, 9H), 0.81 (s, 9H), -0.01 (s, 6H).

Step 2: (2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl N-(*tert*-butoxycarbonyl) glycinate



- To a solution of 22 g of (2Z)-4-([*tert*-butyl(dimethyl)silyl]oxy)-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl N-(*tert*-butoxycarbonyl)glycinate in 100 mL of MeCN, 7 mL of PyHF was added and the resulting mixture was stirred at rt for 1.5 h. The reaction mixture was diluted with 500 mL of toluene and then loaded on silica gel column and washed with EtOAc. The solvent was evaporated to afford 16.9 g of the titled compound. <sup>1</sup>H NMR (500 MHz, acetone-*d*<sub>6</sub>): δ 7.69 (d, 2H), 7.35 (d, 2H), 7.33-7.06 (m, 5H), 6.28 (br s, NH), 5.24 (s, 2H), 4.62 (d, 2H), 3.73 (d, 2H), 3.02 (s, 3H), 1.40 (s, 9H).


- Step 3: (2Z)-4-([N-(*tert*-butoxycarbonyl)glycyl]oxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoic acid



- To a solution of 16.7 g of (2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl N-(*tert*-butoxycarbonyl)glycinate in 100 mL of dichloromethane, 19.2 g of Dess-Martin reagent was added and the resulting mixture was stirred at rt for 1 h. Then 1.5 mL of water was added and the resulted mixture was stirred at rt for 30 min. Then the mixture was filtered and evaporated. The crude thus obtained was dissolved in a solvent mixture of 100 mL of THF with 100 mL of *t*-BuOH. To the resulting mixture, 30 mL of 2-methyl-2-butene was added and followed by the addition of 100 mL of 1.2 M of phosphoric acid and 100 mL of 1 M of NaClO<sub>2</sub>. The resulted mixture was stirred at rt for 30 min. The organic phase was separated and the aqueous phase was extracted with EtOAc. The organic phase was combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and then evaporated. The crude was purified by recrystallization from ether to afford 14.8 g of the titled compound as a white solid. <sup>1</sup>H NMR (500 MHz, acetone-*d*<sub>6</sub>): δ 11.5

(br s, OH), 7.76 (d, 2H), 7.43 (d, 2H), 7.17-7.09 (m, 5H), 6.25 (br s, NH), 5.33 (s, 2H), 3.67 (d, 2H), 3.05 (s, 3H), 1.39 (s, 9H).


Step 4: 6-bromohexyl (2Z)-4-{[N-(*tert*-butoxycarbonyl)glycyl]oxy}-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate



A solution of 1.88 g of (2Z)-4-{[N-(*tert*-butoxycarbonyl)glycyl]oxy}-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoic acid and 9.6 g of 1,6-dibromohexane in 20 mL of DMF was stirred at rt with 550 mg of K<sub>2</sub>CO<sub>3</sub> for 2 h. Then saturated ammonium chloride

solution was added and extracted with EtOAc. The organic layer was combined and washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the residue was purified by flash chromatography over silica gel (5-50% EtOAc/hexane) to afford 2.1 g of the titled compound as a colorless oil. <sup>1</sup>H NMR (500 MHz, acetone-*d*<sub>6</sub>): δ 7.76 (d, 2H), 7.43 (d, 2H), 7.17 (m, 3H), 7.08 (d, 2H), 6.24 (br s, NH), 5.27 (s, 2H), 4.24 (t, 2H), 3.68 (d, 2H), 3.45 (t, 2H), 3.05 (s, 3H), 1.81 (m, 2H), 1.68 (m, 2H), 1.44-1.32 (m, 4H), 1.39 (s, 9H).


Step 5: 6-(nitrooxy)hexyl (2Z)-4-{[N-(*tert*-butoxycarbonyl)glycyl]oxy}-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate



A solution of 2.0 g of 6-bromohexyl (2Z)-4-{[N-(*tert*-butoxycarbonyl)glycyl]oxy}-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate and 1.6 g of AgNO<sub>3</sub> in 50 mL of MeCN was heated to 85 °C for 2 h. The solvent was evaporated and the residue was stirred with EtOAc for 10 min and filtered. The solvent was evaporated and the residue was purified by flash chromatography over silica gel (5-50% EtOAc/hexane) to afford 1.5 g of the titled compound as

a colorless oil.  $^1\text{H}$  NMR (500 MHz, acetone- $d_6$ ):  $\delta$  7.76 (d, 2H), 7.43 (d, 2H), 7.16 (m, 3H), 7.08 (d, 2H), 6.24 (br s, NH), 5.25 (s, 2H), 4.51 (t, 2H), 4.25 (t, 2H), 3.68 (d, 2H), 3.05 (s, 3H), 1.72-1.66 (m, 4H), 1.44-1.35 (m, 4H), 1.39 (s, 9H).

- 5 Step 6 : (2Z)-2-[4-(methylsulfonyl)phenyl]-4-[[6-(nitrooxy)hexyl]oxy]-4-oxo-3-phenylbut-2-enyl glycinate chloride



- To a solution of 1.25 g of 6-(nitrooxy) hexyl (2Z)-4-[[N-(*tert*-butoxycarbonyl) glycyloxy]-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate in 7 mL of Et<sub>2</sub>O at 0°C was added 10 mL of HCl  
 10 2M/Et<sub>2</sub>O. The mixture was stirred overnight then filtered and the solid was washed with cold Et<sub>2</sub>O to afford 950 mg of the title compound as a white solid.  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  8.39 (br s, NH), 7.75 (d, 2H), 7.41 (d, 2H), 7.18 (m, 3H), 7.00 (d, 2H), 5.28 (s, 2H), 4.46 (t, 2H), 4.19 (t, 2H), 3.68 (s, 2H), 1.61-1.56 (m, 4H), 1.34-1.21 (m, 4H).


15

## EXAMPLE 3

5-(nitrooxy)pentyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate

Following the procedure described for the preparation of Example 1, the title compound was isolated as a white solid.

20



$^1\text{H}$  NMR (500 MHz, Acetone):  $\delta$  7.76 (d, 2H), 7.43 (d, 2H), 7.18-7.16 (m, 3H), 7.09-7.07 (m, 2H), 5.18 (s, 2H), 4.50 (t, 2H), 4.26 (t, 2H), 3.05 (s, 3H), 1.90 (s, 3H), 1.76-1.70 (m,




4 H), 1.47-1.41 (m, 2 H).

#### EXAMPLE 4

7-(nitrooxy)heptyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate

5

Following the procedure described for the preparation of Example 1, the title compound was isolated as a white solid.



10


<sup>1</sup>H NMR (500 MHz, Acetone): δ 7.77 (d, 2 H), 7.44 (d, 2 H), 7.18-7.16 (m, 3 H), 7.09-7.07 (m, 2 H), 5.18 (s, 2 H), 4.52 (t, 2 H), 4.24 (t, 2 H), 3.05 (s, 3 H), 1.89 (s, 3 H), 1.72-1.64 (m, 4 H), 1.40-1.34 (m, 6 H).

15

An alternate method for synthesizing Example 1 is as follows:


### ALTERNATE METHOD – EXAMPLE 1

5



### Step 1 – Grignard Carbometallation Reaction

10



A flask is charged with 49.2 ml THF followed by 3-phenyl-2-propyn-1-ol (10.0g, 75.6 mmol). Then a 3.0M solution of methylmagnesium chloride (26.5 mL, 79.4 mmol) is added followed by a 1.8M aryl Grignard reagent (46.2 mL, 83.2 mmol). The reaction vessel is warmed to reflux (65 °C) and maintained for 4 hours.

5 The reaction is then cooled to room temperature (23 °C) and carbon dioxide is bubbled directly into the reaction mixture during which the solution warms to 35°C. The solution is then allowed to age for another 15-30 minutes while maintaining an internal temperature of 35 °C.


10 Next after venting the head space of carbon dioxide, to the reaction mixture is added a 1.0M solution of potassium *t*-butoxide in THF (37.8 mL, 37.8 mmol). This mixture is allowed to age for 40 minutes at which point acetic anhydride (13.9 mL, 147.5 mmol) is added. The reaction is stirred at room temperature (23 °C) for 100 minutes and then additional THF (189 ml) and 45 wt% potassium hydroxide (5.8 ml, 68.1 mmol) are charged. The solution is stirred for 6-10 hours at 40 °C and then is cooled to room temperature. Finally, a 1.4M

15 magnesium chloride solution (132 mL total volume - 38.4g MgCl<sub>2</sub>\*6H<sub>2</sub>O in water) is charged to the vessel and stirred for 15-30 minutes. The organic and aqueous layers are then separated and the organic layer is concentrated down to 180 mL. Next water (9.5 mL) is added to the THF concentrate followed by IPAc (342 mL) and the batch is aged for 2-4 hours at 23 °C, then cooled in an ice bath to 0 °C and aged another 1 hour.

20 Filtration of the crystalline solid followed by rinse with water (100 ml) and cold (0 °C) IPAc (100 mL) provided 15.6 g of the desired crystalline hydrated magnesium salt (82% isolated yield).

### Step 2 – Salt Break Reaction

25




A 125 mL jacketed flask equipped with an overhead paddle stirrer, thermocouple, dropping funnel, Claisen adapter and nitrogen inlet was charged with 80 mL of 2 M acetic acid solution. The acetic acid solution was warmed to 35-40 °C.

5 Separately, dissolved 10.68 g of the crude magnesium salt iii in 20 mL of DMF and transferred the clear dark-yellow solution to the dropping funnel. The DMF solution of magnesium salt iii was then added to the 2 M acetic acid solution at 35-40 °C dropwise over 40 minutes followed by a DMF rinse (4 mL). After the addition is complete the slurry is allowed to cool to ambient temperature. The batch was filtered and washed with 20% DMF in GMP water followed by two GMP water washes.

10 The batch was dried in the vacuum oven dried at 35 °C under vacuum with a nitrogen sweep. Isolated 7.23 g of acid iv as a white crystalline solid for an 88% recovery.

### Step 3 – Oxidation Reaction




15

A mixture of acid iv (10.3 g, 29.2 mmol) in acetic acid (97 mL) was heated to 40 °C and hydrogen peroxide (30%, 12.4 mL, 146 mmol) was added over 30 min. When no sulfoxide remained (8.0 hours), water (194 mL) was added. The mixture was seeded with 0.6% sulfone acid (60 mg) and the temperature was held at 40 °C for 1h then cooled to -10 °C over 2 h and held at this temperature for 15 h. The product was isolated by filtration, washed with water (2 x 27 mL) and dried under vacuum at 50 °C to afford acid v (9.78 g, 89%) as a white crystalline solid.

25

## Step 4 – Coupling Reaction




5

To a 1 L round bottom flask equipped with an overhead stirrer, thermocouple and nitrogen inlet was charged 160 mL of DMF, liquid bromohexanol vi (16.34 g, 88.4 mmol), solid sulfone acid v (30.3 g, 80.4 mmol) and 10 mL of DMF for rinse to give a clear solution at room temperature. To this resulting solution was then added powder  $K_2CO_3$  (11.0 g, 80.4 mmol) in one portion at 20-22 °C, followed by 20 mL of DMF for rinse, and then stirred at 20-22 °C for 30 min and then heated to 40-45 °C for 5 h.

The reaction mixture was cooled to ~20 °C and IPAc (350 mL) was introduced and then ice cold water (180 mL) added slowly to maintain the temperature <30 °C. The mixture was stirred for 0.5 h and settled to give two clear layers. The aqueous layer was separated and back-extracted with IPAc (350 mL). The combined organic layers were washed with water (2 x 180 L). The organic layer was then concentrated *in vacuo* to ~180 mL, and flushed with 180 mL of new IPAc. The resulting concentrated solution was (filtered through a sintered funnel if solid sodium chloride was observed) adjusted the concentration to 170-180 mg/mL (~180 mL, KF <200 µg/mL). To this solution was added 90 mL of n-heptane at 19-20 °C followed by addition of ~0.30 g of the seed, while it was aged for 1-2 h to provide a good seed-bed at 18-20 °C. The remaining n-heptane (270 mL) was introduced over 1-2 h and then aged for additional 8 h. The slurry was cooled to -5 to 0 °C and was then filtered. The cake was washed with cold pre-mixed IPAc/n-heptane (1/4, 150 mL) and air-dried at room temperature under nitrogen for 12 h. The isolated white crystalline solid (36.2 g) was obtained in 94% yield.

25

## Step 5 – Nitration Reaction




5

Nitric acid (90%, 2.30 g, 32.9 mmol) was added to a cooled solution (0 °C) of butyric anhydride (6.27 g, 39.7 mmol) in dichloromethane (46 mL). After an age of 1 hr at 0 °C, the solution was cooled to -10 °C and a solution of the alcohol (10.0 g, 21.1 mmol) in dichloromethane (33 mL) was added over 30 min. The reaction was complete within 1 hour and was quenched by addition of  $\text{K}_3\text{PO}_4$  (33 mL of a 2M aq sol). Toluene (46 mL) was added and the layers separated. The organic layer was then washed with urea solution (83 mL of 0.5 wt% aq sol) before concentration to a volume of approximately 70 mL. Heptane (90 mL) was added and crystallization of the product occurred. The resulting solid was isolated by filtration and dried under a stream of nitrogen to afford the crystalline title compound (10.3 g, 94%) mp 80 °C.

15

## WHAT IS CLAIMED IS:

1. A compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

n is an integer from 3 to 6;

R<sup>1</sup> is selected from the group consisting of:

- (a) S(O)<sub>2</sub>CH<sub>3</sub>,
- (b) S(O)<sub>2</sub>NH<sub>2</sub>,
- (c) S(O)<sub>2</sub>NHC(O)CF<sub>3</sub>,
- (d) S(O)(NH)CH<sub>3</sub>,
- (e) S(O)(NH)NH<sub>2</sub>,
- (f) S(O)(NH)NHC(O)CF<sub>3</sub>,
- (g) P(O)(CH<sub>3</sub>)OH, and
- (h) P(O)(CH<sub>3</sub>)NH<sub>2</sub>;

R<sup>2</sup> and R<sup>3</sup> each are independently selected from the group consisting of:

- (a) hydrogen,
- (b) halo,
- (c) C<sub>1</sub>-6alkoxy,
- (d) C<sub>1</sub>-6alkylthio,
- (e) CN,
- (f) CF<sub>3</sub>,
- (g) C<sub>1</sub>-6alkyl, and
- (h) N<sub>3</sub>;

R<sup>4</sup> is selected from the group consisting of

- (a)  $-C(O)-C_{1-4}alkyl$  and  
 (b)  $-C(O)-(CH_2)_m-N(R^5)(R^6)$ ;

m is an integer from 1 to 4; and

5

$R^5$  and  $R^6$  are each independently selected from the group consisting of hydrogen and  $C_{1-4}alkyl$ , optionally substituted with 1 to 3 halo groups.

10

2. The compound according to Claim 1 wherein

$R^1$  is  $S(O)_2CH_3$ , and

$R^2$  and  $R^3$  are both hydrogen.

15

3. The compound according to Claim 1 wherein n is 3, 4 or 5.


4. The compound according to Claim 3 wherein n is 4.

5. The compound according to Claim 1 wherein  $R^4$  is acetyl.

20

6. The compound according to Claim 1 wherein  $R^4$  is glyciny1.


7. A compound which is



25

8. A compound which is





or a pharmaceutically acceptable salt thereof.

5                    9.        A method of treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound according to Claim 1.

10                  10.       The method according to Claim 9 wherein the patient is also at risk of a thrombotic cardiovascular event and on aspirin therapy to reduce the risk of the thrombotic cardiovascular event.

15                  11.       A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising administering to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1.

20                  12.       The method according to Claim 11 wherein the patient is also at risk of a thrombotic cardiovascular event and on aspirin therapy to reduce the risk of the thrombotic cardiovascular event.

25                  13.       A method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a compound according to Claim 1 in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event.

14. The method according to Claim 13 wherein the compound is administered orally on a once daily basis.

15. The method according to Claim 13 wherein the compound is administered orally on a twice daily basis.

16. The method according to Claim 13 wherein the chronic cyclooxygenase-2 selective mediated disease or condition is selected from the group consisting of: osteoarthritis, rheumatoid arthritis and chronic pain.

17. The method according to Claim 13 wherein aspirin is administered at a dose of about 30 mg to about 1 g.

18. The method according to Claim 17 wherein aspirin is administered at a dose of about 80 to about 650 mg.

19. The method according to Claim 18 wherein aspirin is administered at a dose of about 81 mg or about 325 mg.

20. The method according to Claim 13 wherein aspirin is orally administered once daily.

21. A pharmaceutical composition comprising a compound of formula I, as defined in any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and aspirin in combination with a pharmaceutically acceptable carrier.

22. A pharmaceutical composition comprising a compound of formula I, as defined in any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.



23. A compound according to Claim 1 wherein:  
 $R^1$  is selected from the group consisting of:  $S(O)_2CH_3$  and  $S(O)_2NH_2$ ;  
 $R^2$  and  $R^3$  each are independently selected from the group consisting of: hydrogen and halo; and

R<sup>4</sup> is -C(O)-C<sub>1-4</sub>alkyl.

24. A compound according to Claim 23 wherein n is 4 or 5.

5

25. A compound according to Claim 1 selected from the following group:



10

26. Use of a compound of formula (I), as defined in any one of claims 1 to 8, 23, 24 or 25, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an inflammatory disease.

27. A compound of formula (I), as defined in any one of claims 1 to 8, 23, 24 or 25, or a pharmaceutically acceptable salt thereof, for use in medical therapy.

28. A compound according to claim 27 wherein said therapy is of a cyclooxygenase mediated disease advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA2004/000314

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C317/46 A61K31/216 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07F A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/45703 A (NITROMED) 28 June 2001 (2001-06-28) cited in the application page 4, line 26 - page 5, line 8 page 45, line 10 - page 47, line 22 page 62, line 10 - line 26 page 91, line 27 - page 92, line 3 page 93, line 15 - line 19 page 93, line 29 - line 31; examples 8,9,12,14	1-28
Y	----- WO 96/13483 A (MERCK FROSST CANADA) 9 May 1996 (1996-05-09) page 10, line 30 - page 11, line 21; claims 1,8,9,11	1-28
A	----- WO 97/28120 A (MERCK FROSST CANADA) 7 August 1997 (1997-08-07) claims 1,8,9,12 -----	1-28

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

7 June 2004

Date of mailing of the international search report

08. 07. 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

English, R

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2004/000314

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 9-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA2004/000314

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0145703	A	28-06-2001	AU 2592801 A	03-07-2001
			BR 0017037 A	10-06-2003
			CA 2393724 A1	28-06-2001
			CN 1434712 T	06-08-2003
			EP 1246621 A1	09-10-2002
			JP 2003523958 T	12-08-2003
			WO 0145703 A1	28-06-2001
			US 2003220228 A1	27-11-2003
			US 2001041726 A1	15-11-2001
-----				
WO 9613483	A	09-05-1996	AT 185797 T	15-11-1999
			AU 688980 B2	19-03-1998
			AU 3695095 A	23-05-1996
			CA 2200462 A1	09-05-1996
			WO 9613483 A1	09-05-1996
			DE 69512930 D1	25-11-1999
			DE 69512930 T2	18-05-2000
			EP 0788476 A1	13-08-1997
			ES 2139959 T3	16-02-2000
			JP 10507765 T	28-07-1998
			US 5849943 A	15-12-1998
-----				
WO 9728120	A	07-08-1997	AT 198323 T	15-01-2001
			AU 707199 B2	08-07-1999
			AU 1434697 A	22-08-1997
			CA 2244134 A1	07-08-1997
			WO 9728120 A1	07-08-1997
			CN 1214677 A	21-04-1999
			CZ 9802416 A3	16-12-1998
			DE 69703791 D1	01-02-2001
			DE 69703791 T2	21-06-2001
			EE 9800230 A	15-12-1998
			EP 0882015 A1	09-12-1998
			ES 2152648 T3	01-02-2001
			HU 9902119 A2	28-04-2001
			JP 2000504332 T	11-04-2000
			NO 983511 A	30-09-1998
			NZ 326283 A	23-12-1998
			PL 328225 A1	18-01-1999
			SK 102698 A3	13-04-1999
			US 5733909 A	31-03-1998
-----				

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**